Comparison of biomarker for diagnosis of nitrous oxide abuse: challenge of cobalamin metabolic parameters, a retrospective study.


Journal

Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161

Informations de publication

Date de publication:
Apr 2023
Historique:
received: 17 11 2022
accepted: 11 01 2023
revised: 10 01 2023
pubmed: 24 1 2023
medline: 22 3 2023
entrez: 23 1 2023
Statut: ppublish

Résumé

Recreational use of nitrous oxide (N We retrospectively collected clinical and biological data from 52 patients with known, documented chronic N Plasma homocysteine was almost consistently increased in case of N There is no specific marker of nitrous oxide abuse according to levels of consumption, total vitamin B12 decrease could not be used either as consumption or as severity marker. However, we showed that homocysteine is consistently increased and could be used as marker of recent N

Sections du résumé

BACKGROUND BACKGROUND
Recreational use of nitrous oxide (N
METHODS METHODS
We retrospectively collected clinical and biological data from 52 patients with known, documented chronic N
RESULTS RESULTS
Plasma homocysteine was almost consistently increased in case of N
CONCLUSION CONCLUSIONS
There is no specific marker of nitrous oxide abuse according to levels of consumption, total vitamin B12 decrease could not be used either as consumption or as severity marker. However, we showed that homocysteine is consistently increased and could be used as marker of recent N

Identifiants

pubmed: 36690804
doi: 10.1007/s00415-023-11570-z
pii: 10.1007/s00415-023-11570-z
doi:

Substances chimiques

Vitamin B 12 P6YC3EG204
Nitrous Oxide K50XQU1029
Methylmalonic Acid 8LL8S712J7
Biomarkers 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2237-2245

Informations de copyright

© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.

Références

Garakani A, Jaffe RJ, Savla D et al (2016) Neurologic, psychiatric, and other medical manifestations of nitrous oxide abuse: a systematic review of the case literature. Am J Addict 25(5):358–369. https://doi.org/10.1111/ajad.12372
doi: 10.1111/ajad.12372 pubmed: 27037733
Morris N, Lynch K, Greenberg SA (2015) Severe motor neuropathy or neuronopathy due to nitrous oxide toxicity after correction of vitamin B12 deficiency. Muscle Nerve 51(4):614–616. https://doi.org/10.1002/mus.24482
doi: 10.1002/mus.24482 pubmed: 25297001
Oussalah A, Julien M, Levy J et al (2019) Global burden related to nitrous oxide exposure in medical and recreational settings: a systematic review and individual patient data meta-analysis. J Clin Med 8(4):551. https://doi.org/10.3390/jcm8040551
doi: 10.3390/jcm8040551 pubmed: 31018613 pmcid: 6518054
Vollenbrock SE, Fokkema TM, Leijdekkers VJ, Vahl AC, Konings R, van Nieuwenhuizen RC (2021) Nitrous oxide abuse associated with severe thromboembolic complications. Eur J Vasc Endovasc Surg 62(4):656–657. https://doi.org/10.1016/j.ejvs.2021.05.041
doi: 10.1016/j.ejvs.2021.05.041 pubmed: 34275729
Molloy MJ, Latio IP, Rosen M (1973) Analysis of nitrous oxide concentrations in whole blood. Br J Anaesth 45(6):556–562. https://doi.org/10.1093/bja/45.6.556
doi: 10.1093/bja/45.6.556 pubmed: 4718246
Grzych G, Deheul S, Davion JB et al (2022) Marqueurs biologiques et impact métabolique de la consommation chronique de protoxyde d’azote. Ann Biol Clin 80:4. https://doi.org/10.1684/abc.2022.1729
doi: 10.1684/abc.2022.1729
Duque MA, Kresak JL, Falchook A, Harris NS (2015) Nitrous oxide abuse and vitamin B12 action in a 20-year-old woman: a case report. Lab Med 46(4):312–315. https://doi.org/10.1309/LM0L9HAVXCHF1UQM
doi: 10.1309/LM0L9HAVXCHF1UQM pubmed: 26489675
Kondo H, Osborne ML, Kolhouse JF et al (1981) Nitrous oxide has multiple deleterious effects on cobalamin metabolism and causes decreases in activities of both mammalian cobalamin-dependent enzymes in rats. J Clin Invest 67(5):1270–1283. https://doi.org/10.1172/JCI110155
doi: 10.1172/JCI110155 pubmed: 6112240 pmcid: 370693
Deacon R, Perry J, Lumb M et al (1978) Selective inactivation of vitamin B12 in rats by nitrous oxide. The Lancet 312(8098):1023–1024. https://doi.org/10.1016/S0140-6736(78)92341-3
doi: 10.1016/S0140-6736(78)92341-3
Grzych G, Gernez E, Deheul S, Kim I (2022) Methylmalonic acid: Specific marker of chronic nitrous oxide abuse? Rev Med Interne. https://doi.org/10.1016/j.revmed.2022.01.001 . (Published online February 2022)
doi: 10.1016/j.revmed.2022.01.001 pubmed: 35094872
Wiedemann A, Oussalah A, Lamireau N et al (2022) Clinical, phenotypic and genetic landscape of case reports with genetically proven inherited disorders of vitamin B12 metabolism: a meta-analysis. Cell Rep Med 3(7):100670. https://doi.org/10.1016/j.xcrm.2022.100670
doi: 10.1016/j.xcrm.2022.100670 pubmed: 35764087 pmcid: 9381384
Grzych G, Douillard C, Lannoy J, Joncquel Chevalier Curt M (2020) Very high plasma homocysteine without malnutrition or inherited disorder. Clin Chem 66(11):1468–1469. https://doi.org/10.1093/clinchem/hvaa070
doi: 10.1093/clinchem/hvaa070 pubmed: 33141907
Caré W, Dufayet L, Piot MA et al (2021) Toxicités aiguës et chroniques associées à l’usage et au mésusage du protoxyde d’azote: mise au point. Rev Médecine Interne. https://doi.org/10.1016/j.revmed.2021.10.008 . (Published online December 10, 2021)
doi: 10.1016/j.revmed.2021.10.008
Waclawik AJ, Luzzio CC, Juhasz-Pocsine K, Hamilton V (2003) Myeloneuropathy from nitrous oxide abuse: unusually high methylmalonic acid and homocysteine levels. WMJ 102(4):43–45
pubmed: 12967021
Borovecki A, Borovecki A, Mlinaric A et al (2018) Informed consent and ethics committee approval in laboratory medicine. Biochem Medica. https://doi.org/10.11613/BM.2018.030201
doi: 10.11613/BM.2018.030201
Dyck PJ, O’Brien PC (2006) Polyneuropathy dysfunction scores. J Neurol Neurosurg Psychiatry 77(8):899–900. https://doi.org/10.1136/jnnp.2006.093781
doi: 10.1136/jnnp.2006.093781 pubmed: 16709581 pmcid: 2077639
Lozeron P, Théaudin M, Mincheva Z et al (2013) Effect on disability and safety of Tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy. Eur J Neurol 20(12):1539–1545. https://doi.org/10.1111/ene.12225
doi: 10.1111/ene.12225 pubmed: 23834402
Gorevic P, Franklin J, Chen J, Sajeev G, Wang JCH, Lin H (2021) Indirect treatment comparison of the efficacy of patisiran and inotersen for hereditary transthyretin-mediated amyloidosis with polyneuropathy. Expert Opin Pharmacother 22(1):121–129. https://doi.org/10.1080/14656566.2020.1811850
doi: 10.1080/14656566.2020.1811850 pubmed: 32892660
Rafii M, Elango R, House JD et al (2009) Measurement of homocysteine and related metabolites in human plasma and urine by liquid chromatography electrospray tandem mass spectrometry. J Chromatogr B 877(28):3282–3291. https://doi.org/10.1016/j.jchromb.2009.05.002
doi: 10.1016/j.jchromb.2009.05.002
Blom HJ, Rooij A van, Hogeveen M (2007) A simple high-throughput method for the determination of plasma methylmalonic acid by liquid chromatography-tandem mass spectrometry. Clin Chem Lab Med 45(5):645–650. https://doi.org/10.1515/CCLM.2007.117
doi: 10.1515/CCLM.2007.117 pubmed: 17484628
İspir E, Serdar MA, Ozgurtas T et al (2015) Comparison of four automated serum vitamin B12 assays. Clin Chem Lab Med CCLM 53(8):1205–1213. https://doi.org/10.1515/cclm-2014-0843
doi: 10.1515/cclm-2014-0843 pubmed: 25720078
Hannibal L, Lysne V, Bjørke-Monsen AL et al (2016) Biomarkers and algorithms for the diagnosis of vitamin B12 deficiency. Front Mol Biosci. https://doi.org/10.3389/fmolb.2016.00027 . (Accessed November 9, 2022)
doi: 10.3389/fmolb.2016.00027 pubmed: 27446930 pmcid: 4921487
Clarke R, Refsum H, Birks J et al (2003) Screening for vitamin B-12 and folate deficiency in older persons. Am J Clin Nutr 77(5):1241–1247. https://doi.org/10.1093/ajcn/77.5.1241
doi: 10.1093/ajcn/77.5.1241 pubmed: 12716678
Selhub J, Jacques PF, Dallal G, Choumenkovitch S, Rogers G (2008) The use of blood concentrations of vitamins and their respective functional indicators to define folate and vitamin B12 status. Food Nutr Bull 29(2_suppl1):S67–S73. https://doi.org/10.1177/15648265080292S110
doi: 10.1177/15648265080292S110 pubmed: 18709882
Mirkazemi C, Peterson GM, Tenni PC, Jackson SL (2012) Vitamin B12 deficiency in Australian residential aged care facilities. J Nutr Health Aging 16(3):277–280. https://doi.org/10.1007/s12603-011-0348-2
doi: 10.1007/s12603-011-0348-2 pubmed: 22456786
Nakazato M, Maeda T, Emura K, Maeda M, Tamura T (2012) Blood folate concentrations analyzed by microbiological assay and chemiluminescent immunoassay methods. J Nutr Sci Vitaminol (Tokyo) 58(1):59–62. https://doi.org/10.3177/jnsv.58.59
doi: 10.3177/jnsv.58.59 pubmed: 23007069
Stabler SP (2013) Vitamin B12 deficiency. N Engl J Med 368(2):149–160. https://doi.org/10.1056/NEJMcp1113996
doi: 10.1056/NEJMcp1113996 pubmed: 23301732
Frontiera MS, Stabler SP, Kolhouse JF, Allen RH (1994) Regulation of methionine metabolism: effects of nitrous oxide and excess dietary methionine. J Nutr Biochem 5(1):28–38. https://doi.org/10.1016/0955-2863(94)90006-X
doi: 10.1016/0955-2863(94)90006-X
Gernez E, Deheul S, Tard C, Joncquel M, Douillard C, Grzych G (2023) Plasma methionine and clinical severity in nitrous oxide consumption. Toxics 11(1):12. https://doi.org/10.3390/toxics11010012
doi: 10.3390/toxics11010012
Andrade VM, Dal Pont HS, Leffa DD et al (2014) Methylmalonic acid administration induces DNA damage in rat brain and kidney. Mol Cell Biochem 391(1):137–145. https://doi.org/10.1007/s11010-014-1996-4
doi: 10.1007/s11010-014-1996-4 pubmed: 24532006
McLaughlin BA, Nelson D, Silver IA, Erecinska M, Chesselet MF (1998) Methylmalonate toxicity in primary neuronal cultures. Neuroscience 86(1):279–290. https://doi.org/10.1016/S0306-4522(97)00594-0
doi: 10.1016/S0306-4522(97)00594-0 pubmed: 9692761
Einsiedler M, Voulleminot P, Demuth S et al (2022) A rise in cases of nitrous oxide abuse: neurological complications and biological findings. J Neurol 269(2):577–582. https://doi.org/10.1007/s00415-021-10702-7
doi: 10.1007/s00415-021-10702-7 pubmed: 34245346

Auteurs

Guillaume Grzych (G)

CHU de Lille, Service Hormonologie Métabolisme Nutrition Oncologie, 59000, Lille, France. guillaume.grzych@chu-lille.fr.
CHU de Lille - Centre de Biologie Pathologie Génétique - Service Hormonologie Métabolisme Nutrition Oncologie, 1 boulevard du professeur Jules Leclercq, 59000, Lille, France. guillaume.grzych@chu-lille.fr.

Sylvie Deheul (S)

CHU de Lille, Centre d'Addictovigilance des Hauts-de-France, Centre Anti-Poison, Service de Pharmacologie, 59000, Lille, France.

Emeline Gernez (E)

CHU de Lille, Service Hormonologie Métabolisme Nutrition Oncologie, 59000, Lille, France.

Jean-Baptiste Davion (JB)

CHU de Lille, Clinique de Neurologie, 59000, Lille, France.

Dries Dobbelaere (D)

Medical Reference Center for Inherited Metabolic Diseases, Jeanne de Flandre University Hospital and RADEME Research Team for Rare Metabolic and Developmental Diseases, EA 7364 CHU Lille, 59000, Lille, France.

Louise Carton (L)

CHU de Lille, Centre d'Addictovigilance des Hauts-de-France, Centre Anti-Poison, Service de Pharmacologie, 59000, Lille, France.
CHU de Lille, Service d'Addictologie, 59000, Lille, France.

Isabelle Kim (I)

CHU de Lille, Service Hormonologie Métabolisme Nutrition Oncologie, 59000, Lille, France.

Jean Claude Guichard (JC)

Unité Sanitaire en Milieu Pénitentiaire USMP, 59000, Lille, France.

Marie Girot (M)

CHU Lille, Service des Urgences adultes, F-59000, Lille, France.

Linda Humbert (L)

CHU de Lille, Service d'Endocrinologie, Diabétologie et Maladies métaboliques, 59000, Lille, France.

Anas Bennis (A)

CH de Roubaix, Service de Neurologie, 59100, Roubaix, France.

Marie Joncquel (M)

CHU de Lille, Service Hormonologie Métabolisme Nutrition Oncologie, 59000, Lille, France.

Vincent Chieux (V)

CH Saint Philibert, Laboratoire des hôpitaux du GHICL, 59160, Lomme, France.

Audrey Joly (A)

Agence Régionale de Santé Hauts de France, Amiens, France.

Phénicia Nasserdine (P)

CHU de Lille, Service d'Explorations Fonctionnelles Cardiovasculaires, 59000, Lille, France.

Nathalie Trillot (N)

CHU de Lille, Institut Hématologie Transfusion, 59000, Lille, France.

Claire Douillard (C)

Medical Reference Center for Inherited Metabolic Diseases, Jeanne de Flandre University Hospital and RADEME Research Team for Rare Metabolic and Developmental Diseases, EA 7364 CHU Lille, 59000, Lille, France.
CHU de Lille, Service d'Endocrinologie, Diabétologie et Maladies métaboliques, 59000, Lille, France.

Pascal Pigny (P)

CHU de Lille, Service Hormonologie Métabolisme Nutrition Oncologie, 59000, Lille, France.

Céline Tard (C)

U1172, CHU de Lille, Centre de référence des maladies neuromusculaires Nord, Est, Ile-de-France, Service de neurologie, Lille, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH